公开(公告)号：US20230295175A1

公开(公告)日：2023-09-21

申请号：US18122892

申请日：2023-03-17

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Xin Zhang ,  Xiaowen Peng ,  Ruichao Shen ,  Jiajun Zhang ,  Wei Li ,  Hui Cao ,  Xuri Gao ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention relates to processes for preparing a compound of Formula (A):




or a pharmaceutically acceptable salt or solvate thereof. Compound of Formula (A) and pharmaceutical compositions are useful as SARS-CoV-2 3CL pro inhibitors.

公开(公告)号：US20240132512A1

公开(公告)日：2024-04-25

申请号：US18377105

申请日：2023-10-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Joseph Helble ,  Anthony Toto ,  Jiajun Zhang ,  George G. Wu ,  Yat Sun Or

IPC: C07D487/10 ,  A61K31/407

CPC classification number: C07D487/10 ,  A61K31/407 ,  C07B2200/13

Abstract: The present invention features crystalline forms of Compound I,




including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

公开(公告)号：US12006291B2

公开(公告)日：2024-06-11

申请号：US18095155

申请日：2023-01-10

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Jiajun Zhang ,  Hui Cao ,  Ruichao Shen ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D209/42

CPC classification number: C07D209/42

Abstract: The present invention relates to processes for preparing a Compound (1):




or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.

公开(公告)号：US20230234922A1

公开(公告)日：2023-07-27

申请号：US18095155

申请日：2023-01-10

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Kaicheng Zhu ,  Tao Wang ,  Jiajun Zhang ,  Hui Cao ,  Ruichao Shen ,  Guoqiang Wang ,  George G. Wu ,  Yat Sun Or

IPC: C07D209/42

CPC classification number: C07D209/42

Abstract: The present invention relates to processes for preparing a Compound (1):




or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.